Advicenne SA (3MM) AI Stock Analysis

8 Followers

Advicenne SA

(Frankfurt:3MM)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Rare-disease specializationA focused specialty-pharmaceutical strategy can support differentiated expertise in a defined patient population and reduce dependence on broad primary-care markets. Concentration on rare kidney diseases also creates a clearer platform for advancing and commercializing targeted chronic-care treatments over the medium term.

Negative Factors

Negative equityPersistent negative equity signals a fragile capital structure and materially reduces financial flexibility. It can constrain the company’s ability to absorb setbacks, fund development internally, or negotiate from strength with financing providers, leaving future operations more reliant on capital support.

Advicenne SA (3MM) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 9.48M
Dividend Yield: ―
Average Volume (3M): 691
Price to Earnings (P/E): 220.2
Beta (1Y): 0.53
Revenue Growth: 0.10%
EPS Growth: 99.69%
Country: Germany
Employees: 11
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Advicenne SA Business Overview & Revenue Model

Company Description

Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular...

Advicenne SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:3MM against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ABNX	42Neutral	EUR 74.70M	-7.70	-80.82%	―	-10.38%	-72.05%
FR:ALSEN	41Neutral	EUR 83.68M	-2.03	-54.15%	―	―	6.26%
FR:SIGHT	40Underperform	EUR 18.29M	-1.03	52.39%	―	-610.31%	43.88%
FR:ALNEV	37Underperform	EUR 140.09K	0.00	-26.52%	―	-9.52%	100.00%

* Healthcare Sector Average

Performance Comparison

DE:3MM and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:3MM	Advicenne SA	0.65	-0.92	-58.70%
FR:SIGHT	GenSight Biologics	0.07	-0.03	-27.18%
FR:ABNX	ABIONYX Pharma SA	1.67	-2.49	-59.82%
FR:ALSEN	Sensorion SAS	8.44	-9.06	-51.75%
FR:ALNEV	Neovacs SA	0.07	-248.93	-99.97%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Advicenne SA AI Stock Analysis